국가: 남아프리카
언어: 영어
출처: South African Health Products Regulatory Authority (SAHPRA)
Ranbaxy
OFRAMAX 250 (Injection) OFRAMAX 1 g (Injection) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): OFRAMAX 250 (Injection) OFRAMAX 1 g (Injection) COMPOSITION: Oframax 250 Each vial contains: Ceftriaxone sodium (Sterile) equivalent to ceftriaxone 250 mg Oframax 1 g Each vial contains: Ceftriaxone sodium (Sterile) equivalent to ceftriaxone 1 g PHARMACOLOGICAL CLASSIFICATION: A 20.1.1. Broad and medium spectrum antibiotics PHARMACOLOGICAL ACTION Ceftriaxone is a broad-spectrum cephalosporin with a long plasma elimination half-life of approximately 8 hours in normal adults. Antimicrobial Profile (In vitro sensitivity does not necessarily imply in vivo efficacy). The in vitro spectrum of activity of ceftriaxone encompasses: (a) Gram-positive organisms: Streptococcus pneumoniae, Streptococcus Group A (including Streptococcus pyogenes), Streptococcus Group B (including Streptococcus agalactiae), Streptococcus viridans, Streptococcus bovis (Group D), Staphylococcus aureus (methicillin sensitive). Peptostreptococcus sp., and Clostridium sp. Note: Methicillin-resistant Staphylococcus spp. are resistant to ceftriaxone. Enterococcus faecalis, Enterococcus faecium and Listeria monocytogenes are resistant. (b) Gram-negative organisms: Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae, Neisseria meningitidis, Neisseria gonorrhoeae (including penicillin-resistant strains),Escherichia coli, Klebsiella sp**, Enterobacter sp*, Serratia marcescens, Citrobacter sp., Proteus mirabilis, Indole-positive Proteus (including Morganella morganii), Salmonella sp., Shigella sp., Yersinia pestis and Treponema pallidum (in animal experiments). *Some isolates of these species are resistant to ceftriaxone, due to the production of the chromosomally encoded beta- lactamases. **Some isolates of these species are resista 전체 문서 읽기